文献速递甲状腺与浅表技术与安全CTPET

定量SPECT/CT预测Graves病对甲巯咪唑早期反应的新应用

Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.
PubMed 文献 · Korean J Radiol · 2017-04-03

研究纳入36例Graves病患者,于注射99mTc-高锝酸盐5 mCi后20分钟行定量甲状腺SPECT/CT,探讨%摄取、SUV、功能性甲状腺质量等参数与甲巯咪唑治疗后生化甲功正常时间的关联。单因素Cox回归中初始MMI剂量(p=0.014)、%摄取(p=0.015)和功能性甲状腺质量(p=0.016)为显著预测因子,多因素分析仅%摄取保持显著(p=0.034);%摄取5.0%阈值可区分快反应与慢反应患者(p=0.006)。

要点

  • 定量SPECT/CT的甲状腺%摄取是多因素分析中唯一显著的早期反应预测因子(p=0.034)。
  • %摄取5.0%阈值可将快反应与慢反应Graves病患者区分开(p=0.006)。
  • Graves病患者%摄取6.9±6.4%显著高于历史对照甲功正常者0.8±0.5%(p<0.001)。

核心结论

  • 定量SPECT/CT获得的甲状腺%摄取是Graves病患者对甲巯咪唑早期反应的预测指标。

研究设计与样本

  • 研究纳入2015年4月至2016年1月共36例Graves病患者(男10例、女26例,平均年龄45.3±13.8岁),注射99mTc-高锝酸盐5 mCi后20分钟行定量甲状腺SPECT/CT,分析%摄取、SUV、功能性甲状腺质量(SUVmean×甲状腺体积)及临床/生化变量与MMI治疗后生化甲功正常时间的关联。

诊断标准与关键数值

  • 单因素Cox回归中初始MMI剂量(p=0.014)、%摄取(p=0.015)、功能性甲状腺质量(p=0.016)为甲功正常的显著预测因子;多因素Cox回归仅%摄取显著(p=0.034);%摄取5.0%阈值区分快反应与慢反应患者(p=0.006)。

临床应用与阅片要点

  • 定量SPECT/CT测得的甲状腺%摄取可用于预测Graves病患者对甲巯咪唑的早期反应,%摄取5.0%可作为区分快反应与慢反应患者的参考阈值。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Since Graves' disease (GD) is resistant to antithyroid drugs (ATDs), an accurate quantitative thyroid function measurement is required for the prediction of early responses to ATD. Quantitative parameters derived from the novel technology, single-photon emission computed tomography/computed tomography (SPECT/CT), were investigated for the prediction of achievement of euthyroidism after methimazole (MMI) treatment in GD.

MATERIALS AND METHODS: A total of 36 GD patients (10 males, 26 females; mean age, 45.3 ± 13.8 years) were enrolled for this study, from April 2015 to January 2016. They underwent quantitative thyroid SPECT/CT 20 minutes post-injection of 99mTc-pertechnetate (5 mCi). Association between the time to biochemical euthyroidism after MMI treatment and %uptake, standardized uptake value (SUV), functional thyroid mass (SUVmean × thyroid volume) from the SPECT/CT, and clinical/biochemical variables, were investigated.

RESULTS: GD patients had a significantly greater %uptake (6.9 ± 6.4%) than historical control euthyroid patients (n = 20, 0.8 ± 0.5%, p < 0.001) from the same quantitative SPECT/CT protocol. Euthyroidism was achieved in 14 patients at 156 ± 62 days post-MMI treatment, but 22 patients had still not achieved euthyroidism by the last follow-up time-point (208 ± 80 days). In the univariate Cox regression analysis, the initial MMI dose (p = 0.014), %uptake (p = 0.015), and functional thyroid mass (p = 0.016) were significant predictors of euthyroidism in response to MMI treatment. However, only %uptake remained significant in a multivariate Cox regression analysis (p = 0.034). A %uptake cutoff of 5.0% dichotomized the faster responding versus the slower responding GD patients (p = 0.006).

CONCLUSION: A novel parameter of thyroid %uptake from quantitative SPECT/CT is a predictive indicator of an early response to MMI in GD patients.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Kim HJ, Bang JI, Kim JY, et al. Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease. Korean J Radiol. 2017. PMID: 28458607. doi:10.3348/kjr.2017.18.3.543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。